Success Metrics

Clinical Success Rate
88.2%

Based on 15 completed trials

Completion Rate
88%(15/17)
Active Trials
1(5%)
Results Posted
27%(4 trials)
Terminated
2(9%)

Phase Distribution

Ph phase_2
5
23%
Ph not_applicable
2
9%
Ph phase_1
4
18%
Ph early_phase_1
1
5%
Ph phase_3
4
18%
Ph phase_4
6
27%

Phase Distribution

5

Early Stage

5

Mid Stage

10

Late Stage

Phase Distribution22 total trials
Early Phase 1First-in-human
1(4.5%)
Phase 1Safety & dosage
4(18.2%)
Phase 2Efficacy & side effects
5(22.7%)
Phase 3Large-scale testing
4(18.2%)
Phase 4Post-market surveillance
6(27.3%)
N/ANon-phased studies
2(9.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

78.9%

15 of 19 finished

Non-Completion Rate

21.1%

4 ended early

Currently Active

1

trials recruiting

Total Trials

22

all time

Status Distribution
Active(2)
Completed(15)
Terminated(4)
Other(1)

Detailed Status

Completed15
Terminated2
Withdrawn2
Recruiting1
Not yet recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
22
Active
1
Success Rate
88.2%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (4.5%)
Phase 14 (18.2%)
Phase 25 (22.7%)
Phase 34 (18.2%)
Phase 46 (27.3%)
N/A2 (9.1%)

Trials by Status

recruiting15%
terminated29%
not_yet_recruiting15%
unknown15%
withdrawn29%
completed1568%

Recent Activity

Clinical Trials (22)

Showing 20 of 22 trialsScroll for more
NCT06611202Not Applicable

Enhancing Mobility and Mental Health in Dementia Patients

Not Yet Recruiting
NCT06217731Not Applicable

Inflammatory Markers in Saliva of Patients With Burning Mouth Syndrome

Completed
NCT06133114Phase 4

Psychopharmacological Treatment of Emotional Distress

Recruiting
NCT06357104Phase 4

Detoxification From the Lipid Tract

Completed
NCT02913924Phase 2

Effect of Clonazepam on Cannabis Withdrawal and Relapse in Treatment-seeking Patients

Completed
NCT00810316Phase 1

Evaluate Pharmacokinetics Of Two Different Pharmaceutical Oral Formulations Of Alprazolam And A Clonazepam Tablet In Mexican Healthy Population

Completed
NCT01870024Phase 3

Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status Epilepticus

Completed
NCT02134366Phase 3

Clobazam Use in Epilepsia Partialis Continua - Pilot Study

Terminated
NCT02690844Phase 4

Effectiveness of Mucolox® and Clonazepam in Treatment of Burning Mouth Syndrome

Withdrawn
NCT03061136Phase 4

Clonazepam Effects on Brain Oscillations and Cognition in Schizophrenia

Withdrawn
NCT02374567Phase 3

Pharmacovigilance in Gerontopsychiatric Patients

Terminated
NCT02852577Phase 4

Long Term Treatment of Panic Disorder With Clonazepam or Paroxetine

Completed
NCT02789592Phase 2

Efficacy and Safety of Melatonin PR and Clonazepam in Patients With REM Sleep Behavior Disorder in Parkinson Disease

Unknown
NCT02312908Phase 2

Effect of Clonazepam on REM Sleep Behavior Disorder in Patients With Parkinsonism

Completed
NCT02382029Early Phase 1

Acupuncture Versus Clonazepam in Burning Mouth Syndrome

Completed
NCT00594945Phase 2

Study of Intranasal Clonazepam in Adult Subjects With Epileptic Seizures

Completed
NCT00118417Phase 2

Therapies for Treatment-Resistant Panic Disorder Symptoms

Completed
NCT00282828Phase 4

Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder

Completed
NCT01291316Phase 1

GABAergic Modulation in Pain Transmission in Human: Effect of the GABAA Agonist Clobazam on Peripheral and Central Sensitisation

Completed
NCT01011036Phase 3

Effects of GABA-a-Agonists on Pain Mechanisms: An Experimental Study in Healthy Volunteers

Completed

Drug Details

Intervention Type
DRUG
Total Trials
22